Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Arcturus Therapeutics Holdings Inc. (ARCT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A STATE STREET CORP reports a 6.3% stake in AMENDED FILING ARCTURUS THERAPEUTICS HOLDINGS INC
10/02/2023 144 Form 144 - Report of proposed sale of securities:
09/26/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA Therapeutic to Treat Cystic Fibrosis"
08/14/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDMENT NO. 1 TO Controlled Equity Offering SM Sales Agreement August 7, 2023 CANTOR FITZGERALD & CO. 499 Park Avenue 10022 WELLS FARGO SECURITIES, LLC 30 Hudson Yards New York, New York 10001 William Blair & Company, L.L.C.",
"Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress"
08/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/14/2023 8-K Regulation FD Disclosure  Interactive Data
06/30/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Additional Application for Booster Dose of ARCT-154, Self-Amplifying mRNA Vaccine against COVID-19, Submitted in Japan"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress"
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/17/2023 144 Form 144 - Report of proposed sale of securities:
03/28/2023 8-K Quarterly results
03/17/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
02/10/2023 SC 13G/A ARK Investment Management LLC reports a 7.6% stake in ARCTURUS THERAPEUTICS HOLDINGS INC.
02/10/2023 SC 13G/A Nikko Asset Management Americas, Inc. reports a 5.4% stake in Arcturus Therapeutics Holdings Inc
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.5% stake in Arcturus Therapeutics Holdings Inc.
02/08/2023 SC 13G/A STATE STREET CORP reports a 8.5% stake in AMEMDED FILING ARCTURUS THERAPEUTICS HOLDINGS INC
02/03/2023 SC 13G/A Sumitomo Mitsui Trust Holdings, Inc. reports a 5.4% stake in Arcturus Therapeutics Holdings Inc.
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 16% stake in ARCTURUS THERAPEUTICS HOLDINGS, INC.
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.1% stake in ARCTURUS THERAPEUTICS HOLDINGS INC
01/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
12/27/2022 DEL AM Form DEL AM - Delaying amendment:
12/23/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/13/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy